[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 17, Issue 1 (6-2019) ::
3 2019, 17(1): 1-5 Back to browse issues page
Bone morphogenic protein receptor type 1a (BMPR1A) and Caveolin-1 associated with trastuzumab resistance of breast cancer cells
Department of Biology, University of Sistan and Baluchestan, Zahedan, Iran.
Abstract:   (2120 Views)
Trastuzumab is a specific monoclonal antibody used for therapeutic of the human epidermal growth factor receptor 2 (HER-2) -positive metastatic breast cancer. But, resistance to trastuzumab is a major obstacle in clinical efficiency.  During the past years, several studies have been done to find the mechanisms contributing to trastuzumab resistance. Previous studies have highlighted that bone morphogenic protein (BMP) signaling can indicate a pathway in cancer for sensitizing cells to chemotherapy. Also, it was suggested that Caveolin-1 is essential for the formation of caveolae and endocytic membrane transport and has a critical role in drug resistance and metastasis in cancer. The purpose of this study was to assess the expression of BMP receptor type1A (BMPR1A) and Caveolin-1 genes in compare with trastuzumab-sensitive and resistance BT-474 cells. Trastuzumab-resistant BT474 cells were established by continuous subjection to trastuzumab for six months. Then, an MTT assay was done for determining the resistance. After that, the Expression of BMPR1A and Caveolin-1levels were assessed through real-time PCR. Caveolin-1 expression levels increased significantly (2.4 fold, p<0.05) whereas BMPR1A levels down-regulated significantly (8.26 fold, p<0.05) in BT474-R compared to the parental cells. Our results proposed that BMPR1A and CAV1 regulation take part in BT-474 trastuzumab resistance breast cancer. Therefore, further experiments are required to confirm the role/s of BMPR1A and CAV1 in trastuzumab resistance breast cancer.
Keywords: Breast cancer, Drug resistance, Trastuzumab, CAV1, BMPR1A
Full-Text [PDF 297 kb]   (567 Downloads)    
Article Type: Research Article | Subject: Cellular and Molecular
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

REZAEI Z, DASTJERDI K, KORDI-TAMANDANI D M. Bone morphogenic protein receptor type 1a (BMPR1A) and Caveolin-1 associated with trastuzumab resistance of breast cancer cells. 3 2019; 17 (1) :1-5
URL: http://ijpt.iums.ac.ir/article-1-383-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 17, Issue 1 (6-2019) Back to browse issues page
مجله داروشناسی و درمان شناسی ایران Iranian Journal of Pharmacology and Therapeutics
Persian site map - English site map - Created in 0.05 seconds with 39 queries by YEKTAWEB 4657